PRESSMEDDELANDE
Egetis Therapeutics AB
Stockholm, Sweden, December 30, 2020

Change in the number of shares and votes in Egetis Therapeutics

The number of shares and votes in Egetis Therapeutics AB (publ) (the "Company") has increased during the month of December due to the oversubscribed rights issue, which the Company announced through press releases on 5 October, 28 October, and 25 November 2020, having been registered with the Swedish Companies Registration Office. A total of 38,238,085 shares and votes have been added.

At 30 December 2020, which is the last trading day of the month, the number of shares and votes in the Company amounts to 165,068,560.

For further information, please contact:

Nicklas Westerholm, CEO, Egetis Therapeutics
Tel. +46 (0)73 354 20 62
Email: nicklas.westerholm@egetis.com

This information is information that Egetis Therapeutics AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, on 30 December 2020 at 3:30 pm. CET.

About Egetis Therapeutics

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate® is a first in class drug candidate developed for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial was completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study was initiated in Dec 2020 with the first patient dosed and interim results is planned for 2022. Emcitate holds Orphan Drug Designation in the US and EU and was granted Pediatric Disease designation by the US FDA in November 2020. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that Pledox did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx® will be determined together with our partner Solasia.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.egetis.com